Lipimed

Atorvastatin, the active ingredient in Lipimed, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol levels and reduces cardiovascular risk in adults with hypercholesterolemia or mixed dyslipidaemia.

GNH USA supplies Lipimed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin is indicated for disorders of lipid metabolism and for preventing cardiovascular events. - Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol and total cholesterol. - Primary prevention of cardiovascular disease: lowers the risk of heart attack and stroke in patients without prior events. - Secondary prevention of cardiovascular disease: helps prevent recurrent events in patients with established coronary artery disease. - Mixed dyslipidaemia: improves overall lipid profile by lowering LDL and triglycerides while modestly raising HDL.

Adverse reactions may occur with any medication and should be monitored by a healthcare professional.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Abdominal pain: discomfort in the stomach area. - Nausea: feeling of queasiness. - Constipation: infrequent bowel movements. - Elevated liver enzymes: mild increases in ALT or AST.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury. - Acute liver injury: marked elevation of liver transaminases or jaundice. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Myopathy: muscle weakness with elevated CK levels. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain and vomiting.

Before initiating therapy, certain safety considerations are recommended. - Liver function monitoring: obtain baseline and periodic ALT/AST tests. - Pregnancy avoidance: contraindicated in pregnancy (Category X). - Muscle symptom assessment: discontinue if unexplained muscle pain or weakness occurs. - Drug interaction review: evaluate concomitant medications that affect CYP3A4. - Renal impairment caution: adjust therapy in severe kidney disease. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Atorvastatin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors): can markedly increase atorvastatin levels. - Gemfibrozil: raises risk of myopathy and rhabdomyolysis. - Cyclosporine: elevates plasma concentrations, increasing toxicity risk. - High‑dose niacin: potentiates muscle toxicity. - Colchicine: may enhance risk of severe muscle injury.

Moderate Interactions (Monitor Closely): - Amlodipine: may modestly increase atorvastatin exposure. - Warfarin: monitor INR as statins can affect anticoagulation. - Antacids containing aluminum or magnesium: may reduce absorption; separate dosing by at least 2 hours.